Logo
x

Search

Subscribe Now

sNDA

Boehringer Ingelheim and Eli Lilly Report the US FDA's Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin) to Treat HFpEF

Boehringer Ingelheim and Eli Lilly Report the US FDA's Acceptance of sNDA and Granted Priority Review for Jardiance (empagliflozin...

  • November 12, 2021
Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

  • November 12, 2021
Junshi Reports NMPA's Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Junshi Reports NMPA's Acceptance of sNDA for Toripalimab + CT as 1L Treatment for Advanced or Metastatic Esophageal Squamous Cell...

  • July 30, 2021
Bayer Reports sNDA Submission to US FDA and MAA to EMA for Copanlisib + Rituximab to Treat B-iNHL and Relapsed MZL

Bayer Reports sNDA Submission to US FDA and MAA to EMA for Copanlisib + Rituximab to Treat B-iNHL and Relapsed MZL

  • June 22, 2021
Amgen Reports the US FDA's Acceptance of sNDA for Review of Otezla (apremilast) to Treat Mild-To-Moderate Plaque Psoriasis

Amgen Reports the US FDA's Acceptance of sNDA for Review of Otezla (apremilast) to Treat Mild-To-Moderate Plaque Psoriasis

  • May 6, 2021
The US FDA Extends Review Period of Olumiant's sNDA to Treat Moderate to Severe Atopic Dermatitis

The US FDA Extends Review Period of Olumiant's sNDA to Treat Moderate to Severe Atopic Dermatitis

  • April 7, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.